Cargando…

Optimized combinatorial pMHC class II multimer labeling for precision immune monitoring of tumor-specific CD4 T cells in patients

BACKGROUND: With immunotherapy gaining increasing approval for treatment of different tumor types, scientists rely on cutting edge methods for the monitoring of immune responses and biomarker development in patients. Due to the lack of tools to efficiently detect rare circulating human tumor-specifi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rockinger, Georg Alexander, Guillaume, Philippe, Cachot, Amélie, Saillard, Margaux, Speiser, Daniel E, Coukos, Georges, Harari, Alexandre, Romero, Pedro J, Schmidt, Julien, Jandus, Camilla
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7253008/ https://www.ncbi.nlm.nih.gov/pubmed/32448802 http://dx.doi.org/10.1136/jitc-2019-000435

Ejemplares similares

Quantum dot/pMHC multimers vs. phycoerythrin/pMHC tetramers for identification of HLA-A*0201-restricted pHBV core antigen(18–27)-specific T cells
por: Zhu, Jianmeng, et al.
Publicado: (2017)

MHC class I multimers
por: Sun, Mei-Yi, et al.
Publicado: (2001)

Bedside formulation of a personalized multi-neoantigen vaccine against mammary carcinoma
por: Mohsen, Mona O, et al.
Publicado: (2022)

MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma
por: Engelhard, Victor H, et al.
Publicado: (2020)

Polycomb repressor complex 2 suppresses interferon-responsive MHC-II expression in melanoma cells and is associated with anti-PD-1 resistance
por: James, Jamaal L, et al.
Publicado: (2023)

Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer
por: Cachot, Amélie, et al.
Publicado: (2021)

Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies
por: Minnar, Christine M, et al.
Publicado: (2022)

Systematic comparison with autoimmune liver disease identifies specific histological features of immune checkpoint inhibitor-related adverse events
por: Coukos, Alexander, et al.
Publicado: (2022)

PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma
por: Homicsko, Krisztian, et al.
Publicado: (2023)

TCR/pMHC Optimized Protein crystallization Screen
por: Bulek, Anna M., et al.
Publicado: (2012)

TCRpMHCmodels: Structural modelling of TCR-pMHC class I complexes
por: Jensen, Kamilla Kjærgaard, et al.
Publicado: (2019)

Discovery of CD8 T cell epitopes in Merkel cell polyomavirus through combinatorial encoding with MHC multimers
por: Lyngaa, Rikke, et al.
Publicado: (2013)

In situ delivery of nanoparticles formulated with micron-sized crystals protects from murine melanoma
por: Mohsen, Mona O, et al.
Publicado: (2022)

Understanding TR Binding to pMHC Complexes: How Does a TR Scan Many pMHC Complexes yet Preferentially Bind to One
por: Khan, Javed Mohammed, et al.
Publicado: (2011)

Force Measurements of TCR/pMHC Recognition at T Cell Surface
por: Puech, Pierre-Henri, et al.
Publicado: (2011)

Genome-wide structural modelling of TCR-pMHC interactions
por: Liu, I-Hsin, et al.
Publicado: (2013)

TCR/pMHC Interaction: Phenotypic Model for an Unsolved Enigma
por: Gálvez, Jesús, et al.
Publicado: (2016)

Integrating Experiment and Theory to Understand TCR-pMHC Dynamics
por: Buckle, Ashley M., et al.
Publicado: (2018)

Rapid screening of TCR-pMHC interactions by the YAMTAD system
por: Wang, Lihui, et al.
Publicado: (2022)

Information-Driven Docking for TCR-pMHC Complex Prediction
por: Peacock, Thomas, et al.
Publicado: (2021)

Identification and isolation of high avidity tumor-specific CD8 T cells by experimentally assessing pMHC-TCR binding parameters with soluble pMHC complexes
por: Schmidt, Julien, et al.
Publicado: (2015)

MHC Multimer: A Molecular Toolbox for Immunologists
por: Chang, Jun
Publicado: (2021)

MDR1-EXPRESSING CD4(+) T CELLS WITH TH1.17 FEATURES RESIST TO NEOADJUVANT CHEMOTHERAPY AND ARE ASSOCIATED WITH BREAST CANCER CLINICAL RESPONSE
por: Di Roio, Anthony, et al.
Publicado: (2023)

BND-22, a first-in-class humanized ILT2-blocking antibody, promotes antitumor immunity and tumor regression
por: Mandel, Ilana, et al.
Publicado: (2022)

Cell therapies in ovarian cancer
por: Sarivalasis, Apostolos, et al.
Publicado: (2021)

TCR–pMHC bond conformation controls TCR ligand discrimination
por: Sasmal, Dibyendu K., et al.
Publicado: (2019)

Fluctuations in T cell receptor and pMHC interactions regulate T cell activation
por: Egan, Joseph R., et al.
Publicado: (2022)

Impact of Immunotherapy on CD4 T Cell Phenotypes and Function in Cancer
por: Saillard, Margaux, et al.
Publicado: (2021)

The Era of Cytotoxic CD4 T Cells
por: Cenerenti, Mara, et al.
Publicado: (2022)

Update on combined immunotherapy for the treatment of advanced renal cell carcinoma
por: Gebrael, Georges, et al.
Publicado: (2023)

Single-cell transcriptomics identifies pathogenic T-helper 17.1 cells and pro-inflammatory monocytes in immune checkpoint inhibitor-related pneumonitis
por: Franken, Amelie, et al.
Publicado: (2022)

Vaccination against RhoC induces long-lasting immune responses in patients with prostate cancer: results from a phase I/II clinical trial
por: Schuhmacher, Juliane, et al.
Publicado: (2020)

Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity
por: Santos, João Manuel, et al.
Publicado: (2020)

First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study
por: D'Angelo, Sandra P, et al.
Publicado: (2021)

Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial
por: D'Angelo, Sandra P, et al.
Publicado: (2020)

Concurrent Detection of Circulating Minor Histocompatibility Antigen-Specific CD8(+) T Cells in SCT Recipients by Combinatorial Encoding MHC Multimers
por: Broen, Kelly, et al.
Publicado: (2011)

Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer
por: Melisi, Davide, et al.
Publicado: (2021)

Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammation
por: Marquardt, Viktoria, et al.
Publicado: (2023)

The kinetics of two dimensional TCR and pMHC interactions determine T cell responsiveness
por: Huang, Jun, et al.
Publicado: (2010)

Structural Features of the αβTCR Mechanotransduction Apparatus That Promote pMHC Discrimination
por: Brazin, Kristine N., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_svhupeib3ld1iqtabf43hfe8mb